Paradoxical Tuberculosis Reactions in Patients Without HIV Infection
NCT04052022 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 140
Last updated 2026-04-30
Summary
Background:
Most people with tuberculosis (TB) feel better after starting treatment. But for some people, the opposite happens. They may feel better at first, but then suddenly get worse. This is a paradoxical reaction. Researchers want to better understand what causes this reaction and what happens after someone has it.
Objective:
To learn about paradoxical reactions to TB treatment.
Eligibility:
Adults 18 and older diagnosed with confirmed or suspected TB and currently on treatment for at least 2 weeks, with or without signs/symptoms of a paradoxical inflammatory reaction.
Design:
Participants will be screened with a physical exam and medical history. They will give blood and urine samples.
Eligible participants will visit either the NIH Clinical Center or the Mexico Clinic sites 3 times over 6 to 18 months. Each visit will take 7 hours to complete; visits may be scheduled over more than 1 day. Participants may have more visits if their TB symptoms change.
Participants will give blood, urine, and sputum samples. They will have adverse event assessments. They will have 2 to 3 positron emission tomography/computed tomography (PET/CT) scans. PET/CT scans make pictures of the inside of the body. For this, participants will lie on a table that slides into a donut-shaped scanner. They will get a small amount of radioactive dye through an IV, which is a small plastic tube placed in a vein in the arm using a needle.
Participants may have optional apheresis at the NIH site only. For this, blood is taken from a needle in one arm. White blood cells are separated from the rest of the blood. The rest of the blood is returned through a needle in the other arm.
Conditions
Sponsors & Collaborators
-
National Institute of Allergy and Infectious Diseases (NIAID)
lead NIH
Principal Investigators
-
Maura M Manion, M.D. · National Institute of Allergy and Infectious Diseases (NIAID)
Eligibility
- Min Age
- 18 Years
- Max Age
- 99 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-12-20
- Primary Completion
- 2029-04-30
- Completion
- 2029-04-30
Countries
- United States
- Mexico
Study Locations
More Related Trials
-
Immune Responses to Mycobacterium Tuberculosis (Mtb) in People With Latent Tuberculosis Infection With or Without Concomitant Helminth Infection
NCT02225158 ·Status: TERMINATED
-
A Retrospective Study on the Treatment Pattern and Clinical Prognosis of Severe Tuberculosis Patients
NCT06021041 ·Status: UNKNOWN
-
First-in-Human Trial of the Novel Tuberculosis Vaccine Candidate, H107e/CAF®10b
NCT06050356 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Effect of SARS-CoV-2 Disease on Immune Responses, Disease Severity and Treatment Outcomes in Pulmonary Tuberculosis
NCT04930978 ·Status: RECRUITING
-
A Confirmatory Trial of Adjunctive NAC to Prevent Post Tuberculosis Lung Disease
NCT06909799 ·Status: RECRUITING ·Phase: NA
-
Safety, Tolerability, and Immunogenicity of the Vaccine Candidates ID93 + AP10-602 and ID93 + GLA-SE Administered Intramuscularly in Healthy Adult Subjects
NCT02508376 ·Status: COMPLETED ·Phase: PHASE1
-
Immunology Dysregulation in Lymphadenitis Tuberculosis : An Observational Study Using Patient' Block Paraffins 2019 Until 2021
NCT05202548 ·Status: COMPLETED
-
Training Protocol on the Natural History of Tuberculosis
NCT01212003 ·Status: RECRUITING
-
Potential Role of Microbiome in Tuberculosis
NCT04985994 ·Status: COMPLETED
-
A Multiple Ascending Dose Study With a Dose Formulation Comparison Cohort to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects
NCT02606214 ·Status: TERMINATED ·Phase: PHASE1
-
Clinical Analysis of Safety in Latent Tuberculosis Infection Prophylaxis Treatment
NCT04655794 ·Status: UNKNOWN
-
Evaluation of the Safety, Tolerability, PK of TBAJ-587 in Healthy Adults
NCT04890535 ·Status: COMPLETED ·Phase: PHASE1
-
Adverse Reactions and Efficacy of Fixed-dose Combination Anti-tuberculosis (TB) Drugs
NCT00979290 ·Status: COMPLETED
-
Efficacy and Safety Study of Immunomodulator as an Adjunct Therapy in Pulmonary Tuberculosis (TB) Retreatment Patients
NCT00265226 ·Status: COMPLETED ·Phase: PHASE3
-
TB Nutrition, Immunology and Epidemiology
NCT00170404 ·Status: COMPLETED ·Phase: PHASE3
-
Tuberculosis in China
NCT01071603 ·Status: COMPLETED
-
Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Adults With TB Disease
NCT01424501 ·Status: TERMINATED ·Phase: PHASE2
-
Therapeutic ID93 + GLA-SE Vaccination in Participants With Rifampicin-Susceptible Pulmonary TB
NCT06205589 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Diagnostics and Pharmacotherapy for Severe Forms of TB (DMID 15-0100)
NCT03559582 ·Status: COMPLETED
-
Efficacy and Safety of Immunomodulator as an Adjunct Therapy in New Pulmonary Tuberculosis(Category I) Patients.
NCT00341328 ·Status: COMPLETED ·Phase: PHASE3
-
Adverse Drug Reactions to Anti-TB Drugs in the Treatment of Latent Tuberculosis Infection
NCT03312647 ·Status: UNKNOWN
-
Biodistribution and Pharmacokinetics of Pretomanid in Tuberculosis Patients Using 18F-Pretomanid PET
NCT05609552 ·Status: COMPLETED
-
A Registry of Tuberculosis Cases in the CPCRA
NCT00000785 ·Status: COMPLETED
-
Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in Healthy Volunteers
NCT05537038 ·Status: COMPLETED ·Phase: PHASE1
-
Faster Identification of TB and Evaluation of Drug Resistance in HIV-infected People
NCT00959088 ·Status: COMPLETED